Epigenetic dysregulation is now recognized as a driving factor in a wide variety of diseases including oncologic, developmental, auto-immune, and pathogen-induced disorders. As a result, there is a growing interest in developing epigenetic-focused next generation tool compounds to facilitate a fundamental understanding of the biological mechanisms associated with aberrant epigenetic pathways and potentially therapeutic strategies. The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) in the Eshelman School of Pharmacy has joined forces with the School of Medicine’s Center for Structural Biology (CSB) to create a bench-to-bedside chemical probe/drug discovery initiative at UNC Chapel Hill.
read more…

x-ray crystallography MH proteomics center peptides Protein structural bioinformatics Hooker imaging flow cytometry